News

The Company has licensed an AAV gene therapy and IP from the University of Minnesota to treat patients with Fanconi anemia (FA) disorder and other rare blood diseases.

The Hungarian Nobel-prize winning scientist Albert Szent-Györgyi envisioned cancer cures that go beyond large molecules including genes and proteins, but rather target sub-molecular mechanisms, where the electrons play

Harbin Gloria Pharmaceuticals (Gloria) will design and conduct the trial under the terms of its exclusive license, development, commercialization and supply agreement with Sucampo for Amitiza in China.

The new facility, located near the company’s existing Suzhou site, will help increase production capacity to meet growing demand for Pfizer Consumer Healthcare’s brands in China and the

NTRA-9620 is intended to improve post-resection bowel adaptation as well as patient outcomes, which includes reducing reliance on parenteral nutrition support and increasing enteral nutrition intake. The company

The Phase III trial is planned to be conducted in collaboration with the Gynecologic Oncology Group (GOG) Foundation and will be led by principal investigator from University of

As part of the deal, KODE would secure up to $31m in development and sales milestones, plus royalties on net sales, while Agalimmune will have exclusive rights to

Reslizumab is the company’s investigational humanized monoclonal antibody (mAb), which targets interleukin-5 (IL-5), and is being reviewed as a potential treatment for patients with eosinophilic asthma, despite an

Olipudase alfa is being evaluated to treat nonneurological manifestations of ASMD, also known as Niemann-Pick disease type B, as opposed to type A, which is characterized by neurological